Tirzepatide vs Semaglutide: Which GLP-1 Is Right for You?

Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Semaglutide activates only the GLP-1 receptor. That dual mechanism is why tirzepatide tends to drive more weight loss: GIP appears to enhance insulin sensitivity and may directly increase energy expenditure, on top of the appetite suppression both molecules share.

The brand names you'll hear: Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight loss) — same molecule, same dose ladder, different label. Semaglutide is sold as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (an oral pill version for diabetes). Compounded versions of both exist but are not FDA-approved.

Both are injected once weekly. Both come in pre-filled pens. Both follow a dose-escalation schedule starting low and stepping up every 4 weeks to manage side effects. Where they really diverge is in how they perform in trials.

Tirzepatide wins on raw weight loss numbers. The SURMOUNT-5 trial — the first head-to-head comparison — published in 2024 in *NEJM* showed tirzepatide at its highest dose drove 20.9% average weight loss versus semaglutide's 14.9% over 72 weeks. That's a meaningful 6 percentage point gap.

Across studies, the picture holds. SURMOUNT-1 (tirzepatide): 20.9% average loss. STEP 1 (semaglutide): 14.9% average loss. STEP 5 (long-term semaglutide): 15.2% at 104 weeks. SURMOUNT-4 (long-term tirzepatide): 25.3% at 88 weeks for those who stayed on the drug.

But the average hides the individual range. A third of semaglutide users hit 15%+ weight loss; a third of tirzepatide users hit 25%+. Both medications have people who barely respond (under 5% loss) and people who lose dramatically more than the average. Genetics, diet, sleep, and dose tolerance all matter.

For a sense of when to consider switching from one to the other, our guide on [switching from Wegovy to Zepbound](/blog/switching-from-wegovy-to-zepbound-when-and-how) walks through the practical decision points.

Side effects are similar in pattern but slightly different in frequency. Both medications cause GI side effects — nausea, constipation, diarrhea, occasional vomiting. Both are worst during dose escalations and improve after 4-6 weeks at a stable dose.

In SURMOUNT-5, 44% of tirzepatide users reported nausea versus 35% of semaglutide users during the trial. Constipation: 17% vs 13%. Diarrhea: 22% vs 17%. The differences are real but modest, and many people who don't tolerate one tolerate the other just fine.

Serious adverse events were rare in both groups (under 3%) and similar in nature: gallbladder issues, pancreatitis (very rare), allergic reactions. Both medications carry boxed warnings about thyroid C-cell tumors, based on rodent data — there's no signal in humans, but anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome should avoid both. For more on this, see our [GLP-1 and thyroid safety guide](/blog/glp-1-and-thyroid-safety-what-the-data-shows).

Semaglutide has the stronger cardiovascular evidence right now. The SELECT trial (Lincoff AM, et al., *NEJM*, 2023) followed 17,604 people with obesity and existing heart disease over 3.3 years and found semaglutide reduced major cardiovascular events by 20% — heart attack, stroke, or cardiovascular death. That led the FDA to approve a heart disease indication for Wegovy in 2024.

Tirzepatide doesn't have an equivalent finished cardiovascular outcomes trial yet — the SURPASS-CVOT trial is ongoing and expected to read out in 2026. So if you have established heart disease, semaglutide currently has more direct evidence behind it.

For kidney disease, FLOW (Perkovic V, et al., *NEJM*, 2024) showed semaglutide reduced kidney disease progression by 24% in people with type 2 diabetes. Tirzepatide has shown improvement in kidney markers too but doesn't yet have the same outcomes data.

List prices are close but not identical. Zepbound is around $1,060/month at list price; Wegovy is around $1,350/month. With manufacturer savings cards, both can drop to $25-$550/month depending on commercial insurance status.

Insurance coverage is the real determinant. In 2026, more commercial plans cover GLP-1s for obesity than in past years, but Medicare still does not cover GLP-1s for weight loss alone — it only covers them for diabetes or, since 2024, cardiovascular disease prevention (a niche where semaglutide has an edge because of SELECT).

Compounded versions of both exist and cost $200-$400/month, but they're not FDA-approved and the quality varies significantly. Our [GLP-1 insurance coverage guide](/blog/glp-1-insurance-coverage-2026-complete-guide) walks through specific plans and options.

The decision usually comes down to four factors:

Insurance and cost. Whichever your plan covers — or whichever has the better savings card pricing for your situation — usually wins. Saving $500/month on a medication that drives 15% loss beats paying full price for one that drives 20%.

Other health conditions. Established heart disease tilts toward semaglutide. Type 2 diabetes works with either. Significant weight to lose (50+ pounds) tilts toward tirzepatide for raw potency.

Side effect tolerance. If you've struggled on one with severe nausea or constipation, the other is often better tolerated. Many people switch and find their second medication agrees with them more.

Availability. Supply shortages have hit both drugs at different times. Sometimes the right choice is the one you can actually get filled this month.

Talk to a clinician who has experience with both. The trial data tells you the average; your body tells you what works.

Comparing GLP-1 options is exactly the kind of nuanced decision that benefits from talking it through. Lea knows your medication history, your other meds, and the latest evidence on both molecules — and she can help you frame the specific questions to bring to your provider.